- Home
- WIA vs CHRS Comparison
WIA vs CHRS Comparison
Compare WIA & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIA
- CHRS
- Stock Information
- Founded
- WIA 2003
- CHRS 2010
- Country
- WIA United States
- CHRS United States
- Employees
- WIA N/A
- CHRS N/A
- Industry
- WIA Trusts Except Educational Religious and Charitable
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WIA Finance
- CHRS Health Care
- Exchange
- WIA Nasdaq
- CHRS Nasdaq
- Market Cap
- WIA 186.8M
- CHRS 191.3M
- IPO Year
- WIA N/A
- CHRS 2014
- Fundamental
- Price
- WIA $8.09
- CHRS $1.28
- Analyst Decision
- WIA
- CHRS Strong Buy
- Analyst Count
- WIA 0
- CHRS 4
- Target Price
- WIA N/A
- CHRS $5.38
- AVG Volume (30 Days)
- WIA 39.2K
- CHRS 1.9M
- Earning Date
- WIA 01-01-0001
- CHRS 03-12-2025
- Dividend Yield
- WIA 12.29%
- CHRS N/A
- EPS Growth
- WIA N/A
- CHRS N/A
- EPS
- WIA N/A
- CHRS N/A
- Revenue
- WIA N/A
- CHRS $304,340,000.00
- Revenue This Year
- WIA N/A
- CHRS $2.47
- Revenue Next Year
- WIA N/A
- CHRS N/A
- P/E Ratio
- WIA N/A
- CHRS N/A
- Revenue Growth
- WIA N/A
- CHRS 44.19
- 52 Week Low
- WIA $7.56
- CHRS $0.66
- 52 Week High
- WIA $8.91
- CHRS $2.87
- Technical
- Relative Strength Index (RSI)
- WIA 51.17
- CHRS 39.69
- Support Level
- WIA $8.00
- CHRS $1.38
- Resistance Level
- WIA $8.20
- CHRS $1.45
- Average True Range (ATR)
- WIA 0.08
- CHRS 0.13
- MACD
- WIA 0.02
- CHRS -0.04
- Stochastic Oscillator
- WIA 58.85
- CHRS 7.55
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.